Research  >  Research centres  >  HOPE Research Centre  >  Publications  >  Abstracts and publications
Share:  
|
PAGE
MENU

Abstracts and publications

  1. Hassan S, Hurry M, Seung SJ, Walton RN, Elnoursi A, Scheider KAB, Edwin JJ, Aw ATW. Retrospective cohort study of real-world treatment patterns and overall survival in patients with chronic lymphocytic leukemia (CLL) diagnosed between 2010-2017 in Ontario, Canada. American Society of Clinical Oncology (ASCO); May 29- June 2,2020 (poster).
  2. Seung SJ, Hurry M, Hassan S, Walton RN, Elnoursi A, Scheider KAB, Edwin JJ, Aw ATW. Using real world data to determine health system costs of Canadians diagnosed with chronic lymphocytic leukemia. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2020; May 18-20, 2020 (poster).
  3. Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, Earle CC, Cheung M, Leighl N, Coburn N, DeAngelis C, Evans WK. Health system costs for cancer medications and radiation treatment in the four most common cancers. Journal of Population Therapeutics & Clinical Pharmacology October 2019; 26(3): e34-e35 (poster).
  4. Hassan S, Seung SJ, Hurry M, Walton RN, McGee JD. Examining health system costs of ovarian cancer in Ontario using administrative data. Canadian Centre for Applied Research in Cancer Control (ARCC); May 27-28, 2019 (poster).
  5. Mittmann N, LiuN, MacKinnon M, Seung SJ, Look Hong NJ, Earle CC, Gradin S, Sati S, Buchman S, Wright FC. Does active identification of patients nearing end of life change the use of palliative care and home care services? CADTH Symposium; April 14-16, 2019 (poster).
  6. Mittmann N, Liu N, Cheng SY, Seung SJ, Saxena FE, Look Hong NJ, Earle CC, Cheung M, Leighl N, Coburn N, DeAngelis C, Evans WK. Health system costs for cancer medications and radiation treatment in the four most common cancers. OICR Scientific Meeting; March 21-22, 2019 (poster).
  7. Hassan S, Seung SJ, Templeton JA, Adachi JD, Ashe MC, Clark R, Gibbs JC, Kendler D, Mittmann N, Papaioannou A, Thabane L, Wark JD, Giangregorio LM. Assessing direct and indirect health system costs of The Build Better Bones with Exercise Pilot Trial. Value in Health; October 2018; 21(3): S293 (poster).
  8. Look Hong NJ, Liu N, Wright FC, MacKinnon M, Seung SJ, Earle CC, Gradin S, Sati S, Buchman S, Mittmann N. Assessing the impact of active identification of patient appropriate for palliative care on resource utilization and costs in the final month of life. Value in Health; October 2018; 21(3): S31 (poster).
  9. Seung SJ, Hurry M, Walton RN, Evans WK. Using real world data to determine health system costs of a 5-year non-small cell lung cancer cohort. Value in Health; October 2018; 21(3): S49-50 (poster).
  10. Seung SJ, Hurry M, Walton RN, Evans WK. Stage III unresectable non-small cell lung cancer treatment patterns and costs: an Ontario, Canada analysis. Value in Health; October 2018; 21(3): S51-S52 (poster).
  11. Hassan S, Seung SJ, Templeton JA, Adachi JD, Ashe MC, Clark R, Gibbs JC, Kendler D, Mittmann N, Papaioannou A, Thabane L, Wark JD, Giangregorio LM. Assessing the cost-effectiveness of The Build Better Bones with Exercise Pilot Trial. Journal of Population Therapeutics & Clinical Pharmacology; October 2018; 25(2): e38 (poster).
  12. Seung SJ, Hurry M, Walton RN, Evans WK. Patient characteristics, treatment patterns and survival for unresectable stage III non-small cell lung cancer in Ontario, Canada. Journal of Population Therapeutics & Clinical Pharmacology; October 2018; 25(2): e35 (oral).
  13. Seung SJ, Hurry M, Walton RN, Evans WK. Real world treatment patterns and survival of stage IV non-small cell lung cancer (NSCLC) in Ontario Canada. Journal of Population Therapeutics & Clinical Pharmacology; October 2018; 25(2): e41 (poster).
  14. Seung SJ, Hurry M, Walton RN, Evans WK. Patient characteristics, treatment patterns and survival for unresectable stage III non-small cell lung cancer in Ontario, Canada. Journal of Thoracic Oncology; October 2018; 13(10): s623 (poster).
  15. Seung SJ, Hurry M, Walton RN, Evans WK. Real world treatment patterns and survival of stage IV non-small cell lung cancer (NSCLC) in Ontario Canada. Journal of Thoracic Oncology; October 2018; 13(10): s624 (poster).
  16. Mittmann N, Liu N, MacKinnon M, Seung SJ, Look Hong NJ, Earle CC, Gradin S, Sati S, Buchman S, Wright FC. Active identification of patients appropriate for palliative care - impact on use of palliative care and home care resources. ASCO Survivorship Symposium; Feb 16-17, 2018 (poster).
  17. Cheng SY, DeAngelis C, Seung SJ, Rahman F, Chan K, Earle CC, Mittmann N. Characterizing the utilization of the Trillium Drug Program by an oncology patient population. Value in Health; Oct-Nov 2017; (20)9: A446 (poster).
  18. Seung SJ, Hassan S, Zagorski B, Connors J. Determining the Economic Value of Adding Rituximab to Chemotherapy in Canada. Journal of Population Therapeutics & Clinical Pharmacology; Oct 2017; 24(3): e78 (poster).
  19. Mittmann N, Seung SJ, Cheng SY, Rahman R, Earle CE. Determining the cost of equipment and supplies of radiation therapy departments using Management Information Systems data. ARCC; May 25-26, 2017 (oral presentation).
  20. DeAngelis C, Cheng SY, Rahman F, Seung SJ, Earle CE, Chan K, Mittmann N. Characterizing the utilization of the Trillium Drug Program by an oncology patient population. ARCC; May 25-26, 2017 (poster).
  21. Mittmann N, Earle C, Beglaryan H, Liu N, Gilbert J, Rahman F, Seung SJ, Leblanc D, De Rossi S, Zwicker V, Sussman J. What is the value of Cancer Care Ontario’s Breast Cancer Well Follow-up Care Initiative? OICR Scientific Meeting; March 23-24, 2017 (oral presentation).
  22. Mittmann N, Seung SJ, Cheng SY, Rahman R, Earle CE. Determining the cost of equipment and supplies of radiation therapy departments using Management Information Systems data. OICR Scientific Meeting; March 23-24, 2017 (poster).
  23. DeAngelis C, Cheng SY, Rahman F, Seung SJ, Earle CE, Chan K, Mittmann N. Characterizing the utilization of the Trillium Drug Program by an oncology patient population. OICR Scientific Meeting; March 23-24, 2017 (poster).
  24. Mittmann N, Earle C, Beglaryan H, Liu N, Gilbert J, Rahman F, Seung SJ, LeBlanc D, De Rossi S, Zwicker V, Sussman J. An evaluation of the Breast Cancer Well Follow-Up Care Initiative using administrative databases: a new model of analysis. Journal of Clinical Oncology: ASCO Quality Care Symposium; March 2017; 35(8) (oral presentation).
  25. Mittmann N, Earle C, Liberty J, Beglaryan H, Liu N, Gilbert J, Rahman F, Seung SJ, Zwicker V, Grant M, De Rossi S, Sussman J. Promoting health system sustainability with new models of care: an evaluation of the Breast Cancer Well Follow-up Care Model. Health Quality Transformation; Oct 20, 2016 (poster).
  26. DeAngelis C, Cheng SY, Rahman F, Seung SJ, Earle C, Chan K, Mittmann N. Characterizing the utilization of the Trillium Drug Program by an oncology patient population. Journal of Population Therapeutics and Clinical Pharmacology Oct 2016; 23(3): e209 (oral presentation).
  27. Mittmann N, Seung SJ, Cheng SY, Rahman F, Earle CC. Determining the cost of equipment and supplies of radiation therapy departments using Management Information Systems data. Journal of Population Therapeutics and Clinical Pharmacology 2016; 23(3): e213 (poster).
  28. Mittmann N, Earle C, Beglaryan H, Liu N, Gilbert J, Rahman F, Seung SJ, Zwicker V, Grant M, De Rossi S, Sussman J. An evaluation of the Breast Cancer Well Follow-up Care Initiative using administrative databases: a new model of analysis. Journal of Population Therapeutics and Clinical Pharmacology 2016; 23(3): e219 (poster).
  29. Mittmann N, Seung SJ, Cheng SY, Rahman F, Earle CC. Determining the cost of equipment and supplies of radiation therapy departments using Management Information Systems data. ARCC; May 8-9, 2016 (oral presentation).
  30. DeAngelis C, Cheng SY, Rahman F, Seung SJ, Earle C, Chan K, Mittmann N. Characterizing the utilization of the Trillium Drug Program by an oncology patient population. ARCC; May 8-9, 2016 (poster).
  31. Seung SJ, Cheng SY, Rahman F, Earle CC, Mittmann N. Quantifying costs of medical personnel involved with radiation therapy using administrative databases. ISPOR 18th Annual European Congress, Milan, Italy. Value in Health 2015; 18 (7), A477 (poster).
  32. Mittmann N, Hassan S, Seung SJ, Saherawala H, Hoffstein V, Bradley-Kennedy C. Examining health system and resource utilization and medical management of patients with idiopathic pulmonary fibrosis in Ontario: A Preliminary Analysis. ISPOR 18th Annual European Congress, Milan, Italy. Value in Health 2015; 18(7), A499 (poster).
  33. Mittmann N, Seung SJ, Cheng SY, Liu N, Camacho X, Maclagan L, DeAngelis C, Earle CC. Generating costing algorithms for oncology drugs using administrative databases. ISPOR 18th Annual European Congress, Milan, Italy. Value in Health 2015; 18(7), A691 (poster).
  34. Mittmann N, Hassan S, Seung SJ, Saherawala H, Hoffstein V, Bradley-Kennedy C. An interim analysis of resource utilization and medical management of patients with idiopathic pulmonary fibrosis (IPF) in Ontario. CAPT Annual Meeting 2015, Toronto, Canada. Journal of Population Therapeutics and Clinical Pharmacology 2015; 22(3): e272 (poster).
  35. Seung SJ, Cheng SY, Rahman F, Earle CC, Mittmann N. Quantifying costs of medical personnel involved with radiation therapy using administrative databases. CAPT Annual Meeting 2015, Toronto, Canada. Journal of Population Therapeutics and Clinical Pharmacology 2015; 22(3): e272-3 (poster).
  36. Mittmann N, Seung SJ, Cheng SY, Liu N, Camacho X, Maclagan L, DeAngelis C, Earle CC. Generating costing algorithms for oncology drugs using administrative databases. CAPT Annual Meeting 2015, Toronto, Canada. Journal of Population Therapeutics and Clinical Pharmacology 2015; 22(3): e273 (poster).
  37. Seung SJ, Hassan S, Liu FF, Saherawala H, Shear N, Mittmann N. Examining best supportive care resources and costs in refractory/relapsed psoriasis patients. CAPT Annual Meeting 2015, Toronto, Canada. Journal of Population Therapeutics and Clinical Pharmacology 2015; 22 (3): e274 (poster).
  38. Liu N, Mittmann N, Coyte P, Rebecca Hancock-Howard R, Seung SJ, Earle CC. Phase-specific health care costs of cervical cancer: estimates from a population-based study. ARCC Montreal May 24-25, 2015 (oral presentation).
  39. Mittmann N, Seung SJ, Cheng S, Liu N, Camacho X, Maclagan L, DeAngelis C, Earle CC. Generating Costing Algorithms for Oncology Drugs using Administrative Databases. ARCC Montreal May 24-25, 2015 (poster).
  40. Cheung MC, Earle CC, Ho T, Rangrej J, Liu N, Barbera L, Saskin R, Porter J, Seung SJ, Mittmann N. The impact of aggressive management and palliative care on cancer costs in the final month of life. ARCC Montreal May 24-25, 2015 (poster).
  41. Heelan K, Shear N, Knowles S, Hassan S, Mittmann N. A comparison of resource utilization and costs in patients with pemphigus and pemphigoid 6 months before and 6 months after rituximab treatment. Journal of Population Therapeutics and Clinical Pharmacology. 2014; 21(1): e141.
  42. Mittmann N, Porter J, Rangrej J, Seung SJ, Saskin R, Cheung MC, Leighl NB, Hoch JS, Trudeau M, Evans WK, Dainty KN, DeAngelis C, Earle CC. First two years of health system resources and costs following a stage defined breast cancer diagnosis: a population-based approach. Canadian Association for Population Therapeutics (CAPT). Toronto, November 2-4, 2014 (poster).
  43. Naik H, Howell D, Qiu X, Brown C, Vennettilli A, Irwin M, Pat V, Solomon H, Wang T, Hon H, Eng L, Mahle M, Tiessen M, Thai H, Ho V, Pringle D, Xu W, Seung SJ, Mittmann N, Liu G. Canadian cancer site-specific health utility values: Creating the basis for measuring value and costs of therapy. ASCO Quality Care Symposium. Boston, Massachusetts, October 17-18, 2014 (poster).
  44. Mittmann N, Hassan S, Patel J, Tinmouth J. Cost-effectiveness of directly mailed FOBT kits in a hard to reach population in colorectal cancer screening. 6th Annual Meeting OICR/CCO Health Services Research Program. Toronto, Canada. June 19, 2014 (poster).
  45. Cheung M, Earle CC, Ho T, Rangrej J, Liu N, Barbera L, Saskin R, Porter J, Seung SJ, Mittmann N. The impact of aggressive management and palliative care on end-of-life cancer costs. 6th Annual Meeting OICR/CCO Health Services Research Program. Toronto, Canada, June 19, 2014 (poster).
  46. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch J, Evans W, Leighl N, Trudeau M, Earle CC. Population-based utilization of radiation therapy by a Canadian breast cancer cohort. 6th Annual Meeting OICR/CCO Health Services Research Program. Toronto, Canada, June 19, 2014 (poster).
  47. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Leighl N, Hoch J, Trudeau M, Evans W, Earle CC. Homecare utilization and costs in stage IV lung cancer: A Canadian public payer experience. 6th Annual Meeting OICR/CCO Health Services Research Program. Toronto, Canada, June 19, 2014 (poster).
  48. Mittmann N, Porter J, Rangrej J, Seung SJ, Liu N, Saskin R, Cheung M, Leighl N, Hoch J, Trudeau M, Evans W, Dainty KN, DeAngelis C, Earle CC. First two years of health system resources and costs following a stage defined breast cancer diagnosis: a population-based approach. 6th Annual Meeting OICR/CCO Health Services Research Program. Toronto, Canada, June 19, 2014 (poster).
  49. Mittmann N, Seung SJ, Porter J, Rangrej J, Liu N, Trudeau M, DeAngelis C, Hoch J.S, Leighl N, Earle CC. Stage-based utilization of chemotherapy agents in a Canadian breast cancer population. 6th Annual Meeting OICR/CCO Health Services Research Program. Toronto, Canada, June 19, 2014 (poster).
  50. Mittmann N, Porter J, Rangrej J, Seung SJ, Saskin R, Cheung M, Leighl N, Hoch J, Trudeau M, Evans W, Dainty KN, DeAngelis C, Earle CC. First two years of health system resources and costs following a stage defined breast cancer diagnosis: a population-based approach. ISPOR 19th Annual International Meeting, Montreal, (May 31-June 4, 2014) A97.Value in Health 2014; 17(3): A97.
  51. Mittmann N, Hassan S, Seung SJ, Bannon G, Cheung M, Fraser G, Fine S, Kuriakose B. Health care resource utilization in the management of chronic lymphocytic leukemia at an Ontario cancer centre. ISPOR 19th Annual International Meeting, Montreal, (May 31-June 4, 2014) Value in Health 2014; 17(3): A79.
  52. Mittmann N, Seung SJ, Liu N, Porter J, Rangrej J, Trudeau M, DeAngelis C, Hoch JS, Leighl N, Earle CC. Stage-based utilization of chemotherapy agents in a breast cancer population. ARCC 2014, Canadian Centre for Applied Research in Cancer Control. Toronto, Canada, May 11-12, 2014 (poster).
  53. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch J, Evans W, Leighl N, Trudeau M, Earle C. Population based trends in radiation therapy for a Canadian breast cancer cohort. ARCC 2014, Canadian Centre for Applied Research in Cancer Control. Toronto, Canada, May 11-12, 2014 (poster).
  54. Mittmann N, Hassan S, Seung SJ, Bannon G, Cheung M, Fraser G, Fine S, Kuriakose B. Health care resource utilization in the management of chronic lymphocytic leukemia at an Ontario cancer centre. ARCC 2014, Canadian Centre for Applied Research in Cancer Control. Toronto, Canada, May 11-12, 2014 (poster).
  55. Mittmann N, Seung SJ, Cheung M, Saskin R, Porter J, Rangrej J, Trudeau M. DeAngelis C, Hoch JS, Leighl N, Evans W, Dainty K, Earle C.C. First two years of health system resources and costs following a stage defined breast cancer diagnosis: a population-based approach. ARCC 2014, Canadian Centre for Applied Research in Cancer Control. Toronto, Canada, May 11-12, 2014 (oral).
  56. Naik H, Qiu X, Brown MC, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Gonos C, Chaarow R, Pat V, Irwin M, Herzog L, Eng L, Pringle D, Ho A, Xu W, Howell D, Seung SJ, Liu G, Mittmann N. The willingness of cancer patients to regularly complete the EQ-5D health utility questionnaire. ARCC 2014, Canadian Centre for Applied Research in Cancer Control. Toronto, Canada, May 11-12, 2014 (poster).
  57. Naik H, Qiu X, Brown CM, Eng L, Pringle d, Mahler M, Hon H, Tiessen K, Thai H, Ho V, Pat V, Chaarow R, Herzog L, Ho A, Xu W, Howell D, Seung SJ, Mittmann N, Liu G. Characterizing health utility values of Canadian cancer patients. ARCC 2014, Canadian Centre for Applied Research in Cancer Control. Toronto, Canada, May 11-12, 2014 (poster).
  58. Seung SJ, Bannon G, Barbera L, Myers J, Krahn M, Peacock S, Leighl N, Hoch J, Earle C, Mittmann N. Creation of a reference set of the health preference values in oncology: a pilot study using an electronic data collection system. Canadian Association for Population Therapeutics (CAPT). Toronto, Canada (November 17-19, 2013) Journal of Population Therapeutics and Clinical Pharmacology 2014; 21(1): e123.
  59. Seung SJ, El-Hadi W, Raymond V, Bannon G, Mittmann N. Cost-effectiveness analysis of apixaban compared to warfarin for stroke prevention in atrial fibrillation (SPAF) in Canada. Canadian Association for Population Therapeutics (CAPT). Toronto, Canada (November 17-19, 2013) Journal of Population Therapeutics and Clinical Pharmacology 2014; 21(1): e131.
  60. Tseng E, Mittmann N, Seung SJ, Callum J, Prica A, Wells RA, Kim T, Buckstein R. Transfusion-related costs before and after treatment with azacitidine in higher-risk myelodysplastic syndrome. Canadian Association for Population Therapeutics (CAPT). Toronto, Canada (November 17-19, 2013) Journal of Population Therapeutics and Clinical Pharmacology 2014; 21(1): e133.
  61. Mittmann N, Bannon G, Hassan S, Seung SJ, Kee P, Cartolano NS, Pinto PM, Smith K, Craven BC. Interim results from the burden of bowel dysfunction in spinal cord injury study. Canadian Association for Population Therapeutics (CAPT). Toronto, Canada (November 17-19, 2013) Journal of Population Therapeutics and Clinical Pharmacology 2014; 21(1): e140.
  62. Mittmann N, Knowles S, Heelan K, Bannon G, Seung SJ, Shear N. Physician Experience with Rituximab to Treat Pemphigus Vulgaris in Canada: a Questionnaire-Based Study. Canadian Association for Population Therapeutics (CAPT). Toronto, Canada (November 17-19, 2013) Journal of Population Therapeutics and Clinical Pharmacology 2014; 21(1): e146.
  63. Heelan K, Shear N, Knowles S, Hassan S, Mittmann N. Resource Utilization and Costs Associated with Rituximab Treatment in Patients with Pemphigus and Pemphigoid: A Comparison of 6 Months Before and 6 Months After Treatment. Value in Health. 2013; 16(7) A382.
  64. Mittmann N, Seung SJ, Porter J., Rangrej J., Liu N., Trudeau M.2, DeAngelis C., Hoch J.S., Leighl N., Earle CC. Stage -Based Utilization of Chemotherapy Agents in a Canadian. Breast Cancer Population. ISPOR 16th Annual European Congress, Dublin, Ireland. Value in Health 2013; 16(7) A426.
  65. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Hoch J, Evans W, Leighl N, Trudeau M, Earle CC. Population Based Utilization of Radiation Therapy by a Canadian Breast Cancer Cohort. ISPOR 16th Annual European Congress, Dublin, Ireland. Value in Health 2013; 16(7) A430.
  66. Mittmann N, Bannon G., Hassan S, Seung SJ, Kee P, Cartolano NS., Pinto PM, Smith K., Craven C., Wolfe D. Interim Results from the Burden of Bowel Dysfunction in Spinal Cord Injury Study. ISPOR 16th Annual European Congress, Dublin, Ireland. Value in Health 2013; 16(7) A496.
  67. Mittmann N, Knowles S., Heelan K., Bannon G, Seung SJ, Shear N. Physician Experience with Rituximab to Treat Pemphigus Vulgaris in Canada: A Questionnaire -Based Study. ISPOR 16th Annual European Congress, Dublin, Ireland. Value in Health 2013; 16(7) A510.
  68. Mittmann N, Seung SJ, Liu N, Porter J, Saskin R, Leighl NB, Hoch JS, Trudeau M, Evans WK, Earle CC. Homecare utilization and costs in Stage IV lung cancer: a Canadian public payer experience. European Cancer Congress; Amsterdam, The Netherlands. Sep 27-Oct 1, 2013. P011 (poster).
  69. Martinez MCR, Berry SR, Ko YJ, Mittmann N, Lien K, Hassan S, Giotis A, Chan KK. Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2013; 31:(15 suppl 1).
  70. Tseng E, Seung SJ, Mittmann N, Callum J, Buckstein R. Utilization and Costs of Red Blood Cell Transfusions Pre- and Post-Azacitidine in Higher-Risk Myelodysplastic Syndromes. 54th American Society of Hematology Annual Meeting (ASH); Atlanta, USA. Dec. 8-12, 2012. Abstract 4261 (poster).
  71. Seung SJ, Mittmann, N, Hassan S, Bannon G, Craven BC. Preliminary results from the baseline questionnaire of the Burden of Bowel Dysfunction in Spinal Cord Injury Study. Canadian Association for Population Therapeutics (CAPT); Montreal, Canada. May 6-8, 2012 (poster).
  72. Mittmann N, Chan BC, Seung SJ, Liovas A, Cohen E. Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: results from the PLATO study. ISPOR 14th Annual European Congress, Nov 5-8, 2011; Madrid Spain. Value in Health 2011: 14(7): PCV81.
  73. Mittmann N, Seung SJ, Cote R, Hill M, Mackay A, Shuaib A, Hachninski V, Gladstone D, Buck B, Howse D, Gubitz G, Teal P, Sharma M. Indirect stroke costs: the economic burden of ischemic stroke (BURST) in the first 6 months post stroke. 2nd Canadian Stroke Congress; Ottawa, Canada. October 2 - 4, 2011. Stroke 2011: 42(11); E591 abstract # 0.20.
  74. Tam V, Ko YJ, Mittmann N, Chan K, Hassan S, Cheung M, Kumar K. Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. Journal of Clinical Oncology. 2011; 29(15s).
  75. Hassan S, Mittmann N. A Cost Benefit Analysis of the 21-gene Breast Cancer Assay Within a Canadian Health Care System. Journal of Clinical Oncology. 2011; 29(15s).
  76. Seung SJ, Mittmann N. A survey of Canadian stakeholders about OctreoScan utilization. Presented at the annual conference of Canadian Association for Population Therapeutics; Toronto, Canada. March 28-30, 2010. Canadian Journal of Clinical Pharmacology 2010, 17(1): e99. (poster).
  77. Seung SJ, Mittmann N, Sharma M, and The BURST Study Investigators. Resource use after an ischemic stroke: results from The BURST Study. Presented at the annual conference of Canadian Association for Population Therapeutics. Toronto, Canada (March 28-30, 2010). Canadian Journal of Clinical Pharmacology 2010, 17(1): e100. (poster).
  78. Mittmann N, Seung, SJ, Sharma, M. Impact of Disability Status on Ischemic Stroke Costs. International Stroke Conference; San Antonio, USA. February 23-26, 2010. Stroke: published online Feb. 22, 2010. e137.
  79. Seung SJ, Mittmann N, Sharma M. Thirty-day resource use diary data from the BURST study. International Society of Pharmacoeconomics and Outcomes Research. Toronto, Canada. Value in Health 2008; 11(3): A203.
  80. Piwko C, Vicente C, Markus GE, Kappor A, Seung SJ, Mittmann N. Non-injectable insulin - to pay or not to pay? International Society of Pharmacoeconomics and Outcomes Research. Toronto, Canada. Value in Health 2008; 11(3): A239.
  81. Seung SJ, Mittmann N, Sharma M, The BURST Investigators. Caregiver Utilization after an Ischemic Stroke: Preliminary Results from The BURST Study (abstract 3594). International Stroke Conference; New Orleans, USA. February 20-22, 2008. Abstract 3594.
  82. Mittmann N, Seung SJ, Sharma M, The BURST Investigators. Disability and Health Preference after an Ischemic Stroke: Preliminary Results from The BURST Study. International Stroke Conference; New Orleans, USA. February 20-22, 2008. Abstract 3605.
  83. FitzGerald JM, Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C. Economic Burden of Moderate and Severe COPD Exacerbations in Canada (abstract A54). American Journal of Respiratory and Critical Care Medicine. April 2007. 175 (abstracts issue): A135.
  84. Mittmann N, Seung SJ, Pisani N, Callum J, Smith T. Direct Medical Costs of Severely Bleeding Trauma Patients: A Canadian Tertiary Hospital Perspective (abstract 51). Canadian Journal of Clinical Pharmacology. Winter 2006. 13(1): e153.
  85. Mittmann N, Seung SJ, Sharma M, Liovas A, The BURST Investigators. The Economic Burden of Ischemic Stroke Study (“BURST”): Canadian Preliminary Results (abstract 91). Canadian Journal of Clinical Pharmacology. Winter 2006. 13(1): e173.
  86. Seung SJ, Mittmann N, Gladstone DJ, Hassan S. Estimating the Wait Times for Physiotherapy and Occupational Therapy of Hospitalized Ischemic Stroke Patients (abstract 59). Canadian Journal of Clinical Pharmacology. Winter 2006. 13(1): e157.
  87. Mittmann N, Seung SJ, Sharma M, Gladstone DJ, Bailey P, Phillips S, Shuaib A, Hill M, Liovas A. The Economic Burden of ischemic Stroke Study (“BURST”): Preliminary Clinical Data (podium presentation D-03). The Canadian Journal of Neurological Sciences. May 2006. 33(Supp 1): S14.
  88. Seung SJ, Mittmann N, Gladstone DJ, Hassan S. Amount of Physiotherapy and Occupational Therapy for Hospitalized Ischemic Stroke Patients (podium presentation D-02). The Canadian Journal of Neurological Sciences. May 2006. 33(Supp 1): S14.
  89. Mittmann N, Valgimigli M, Percoco G, Squasi P, Arcozzi C, Malagutti P, Ferrari R, Seung SJ, Isogai P. Economic Analysis of the STRATEGY Study: Tirofiban and Drug Eluting Stents versus Abciximab and Bare Metal Stents (podium presentation). Value in Health. Nov 2005. 8(6): A11.
  90. Seung SJ, Mittmann N, Sharma M, Fisher A, Cousineau D, Liovas A. The Methodology Behind a Prospective Observational Study of the Economic Burden of Ischemic Stroke (abstract PST10). Value in Health. Nov 2005. 8(6): A153.
  91. Mittmann N, Seung SJ, Pisani N, Callum J, Smith T. Burden of Illness in Trauma Patients: A Canadian Tertiary Hospital Perspective (abstract 37). Canadian Journal of Clinical Pharmacology. Winter 2005. 12 (1): e59.
  92. Seung SJ, Mittmann N, Haiderali A. Direct Medical Costs (2004) of Acute Care for Stroke in Ontario (abstract 66). Canadian Journal of Clinical Pharmacology. Winter 2005. 12(1): e73.
  93. Seung SJ, Mittmann N, Liovas A. Quantifying Warfarin and INR Monitoring Practices of Physicians in Ontario (abstract 108). Canadian Journal of Clinical Pharmacology. Winter 2005. 12(1): e94.

Technology reports

  1. Brown A, Mittmann N, Seung SJ, Cohen EA, Oh PI, Tang Z, Noorani H, Mensinkai S. Economic Evaluation of Glycoprotein IIb/IIIa in Patients Undergoing Percutaneous Coronary Intervention with Stenting [Technology report no 54]. Ottawa: Canadian Coordinating Office for Health Technology Assessment, March 2005.
  2. Mittmann N, Brown A, Seung SJ, Coyle D, Cohen EA, Brophy J, Title L, Oh P. Economic Evaluation of Drug Eluting Stents [Technology report no 53]. Ottawa: Canadian Coordinating Office for Health Technology Assessment, February 2005.